About Diakonos
Diakonos is a company based in Houston (United States) founded in 2022.. Diakonos has raised $31.4 million across 2 funding rounds from investors including Baylor College of Medicine, Restem and Brain Tumor Investment Fund. Diakonos offers products and services including DOC1021. Diakonos operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Houston, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Diakonos Oncology Corp.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$31.4 M (USD)
in 2 rounds
-
Latest Funding Round
$20 M (USD), Seed
Jun 01, 2025
-
Investors
Baylor College of Medicine
& 2 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Diakonos
Diakonos offers a comprehensive portfolio of products and services, including DOC1021. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Vaccine that stimulates immune response against cancer by mimicking viral infections.
Funding Insights of Diakonos
Diakonos has successfully raised a total of $31.4M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $20 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Seed — $20.0M
-
First Round
First Round
(26 Aug 2024)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2025 | Amount | Seed - Diakonos | Valuation |
investors |
|
| Aug, 2024 | Amount | Seed - Diakonos | Valuation | Restem |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Diakonos
Diakonos has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Baylor College of Medicine, Restem and Brain Tumor Investment Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Philanthropic capital is invested to advance brain tumor treatments.
|
Founded Year | Domain | Location | |
|
Health science courses and degrees are offered to students.
|
Founded Year | Domain | Location | |
|
Advances cell therapies for autoimmune conditions through proprietary platforms.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Diakonos
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Diakonos
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Diakonos Comparisons
Competitors of Diakonos
Diakonos operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Diakonos
Frequently Asked Questions about Diakonos
When was Diakonos founded?
Diakonos was founded in 2022 and raised its 1st funding round 2 years after it was founded.
Where is Diakonos located?
Diakonos is headquartered in Houston, United States. It is registered at Houston, Texas, United States.
Who is the current CEO of Diakonos?
Mike Wicks is the current CEO of Diakonos.
Is Diakonos a funded company?
Diakonos is a funded company, having raised a total of $31.4M across 2 funding rounds to date. The company's 1st funding round was a Seed of $11.4M, raised on Aug 26, 2024.
What does Diakonos do?
Diakonos was founded in 2022 and is headquartered in Houston, United States. Operations focus on the oncology sector, where immunotherapeutics are developed for cancer treatment. Services include dendritic cell vaccines targeting glioblastoma, pancreatic cancer, and sarcoma; intratumoral injections for bone and head and neck cancers; and CAR T cell therapies for HER2-positive breast cancer and solid tumors.
Who are the top competitors of Diakonos?
Diakonos's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Diakonos offer?
Diakonos offers DOC1021.
Who are Diakonos's investors?
Diakonos has 3 investors. Key investors include Baylor College of Medicine, Restem, and Brain Tumor Investment Fund.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.